Results 201 to 210 of about 13,925,210 (307)

An application of weighted support vector machines to individualized second-line therapy selection after levodopa in Parkinson's disease. [PDF]

Front Hum Neurosci
Pham CT, Schneider RB, Venuto CS, Smith G, Brehm ZP, McDermott MP, Ertefaie A.   +6 more
europepmc   +1 more source

Retiring the language of first-line and second-line ART

The Lancet HIV
Vitoria, Marco, Meintjes, Graeme, Ford, Nathan, Frigati, Lisa, Sugandhi, Nandita, Calmy, Alexandra   +5 more
openaire   +2 more sources

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis. [PDF]

Hepatol Commun
Laschtowitz A, Vom Endt C, Kluge M, Pohl J, Frohme J, Wiering L, Vonderlin J, Greverath LM, Horn P, Püngel T, Zöllner C, Benckert J, Engelmann C, Roßner F, Demir M, Tacke F, Peiseler M.   +16 more
europepmc   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions. [PDF]

Int J Mol Sci
Periferakis A, Troumpata L, Xefteris I, Mavrokefalos AK, Periferakis AT, Periferakis K, Caruntu A, Scheau AE, Dragosloveanu CDM, Caruntu C, Scheau C.   +10 more
europepmc   +1 more source

Second Lining

openaire   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source

Correction to 'FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study'. [PDF]

Liver Int
europepmc   +1 more source

Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System. [PDF]

Front Endocrinol (Lausanne)
Dos Santos Nunes Nogueira V, Binowski G, Bronikowska M, Schmidt F, Gueron B, Paiva H, Kossi SD.   +6 more
europepmc   +1 more source